PARSIPPANY, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark I. Froimson, M.D. to its board of directors. Dr. Froimson is currently serving as the President of the American Association of Hip and Knee Surgeons (AAHKS). Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states.
"Mark's deep clinical expertise along with his proven executive track record of driving medical innovation will be an exceptional resource to Pacira as we advance our corporate mission to provide non-opioid pain control to as many postsurgical patients as appropriate," said Dave Stack, chairman and chief executive officer of Pacira. "Mark's leadership at Trinity Health has given him unique and relevant insights into refining patient care, especially those at risk for opioid dependence and addiction. We welcome Mark and look forward to his contributions to the Pacira Board of Directors."
Prior to his executive leadership position at Trinity Health, Dr. Froimson was president and chief executive officer of Euclid Hospital, a Cleveland Clinic Hospital. Dr. Froimson served as a staff surgeon in the Department of Orthopedic Surgery at the Cleveland Clinic for over 16 years, during which time he held a variety of leadership positions including president of the professional staff, vice chair of the Orthopedic and Rheumatologic Institute, and member of the Board of Governors and Board of Trustees.
Dr. Froimson received a B.S. in philosophy from Princeton University, an M.D. from Tulane University School of Medicine and an MBA from the Weatherhead School of Business at Case Western Reserve University. He completed his general surgical and orthopedic training at the University of California, Los Angeles and Columbia-Presbyterian Medical Center. He completed his fellowship in adult reconstructive surgery at the University Hospitals of Cleveland.
Dr. Froimson's publications include authoring book chapters, abstracts and articles in scientific journals, such as the Journal of Arthroplasty, the Journal of Bone and Joint Surgery, the Cleveland Clinic Journal of Medicine and the American Journal of Orthopedics. In addition, he serves in an editorial capacity for numerous scientific publications.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Susan Mesco, (973) 451-4030
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
Source: Pacira Pharmaceuticals, Inc